Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies

Inclusion Criteria: * Understand and sign a written IRB-approved informed consent form. * Have a histologically confirmed solid tumor. * Have progressive disease following standard/approved chemotherapy or have no appropriate alternative therapy available. * Have one or more tumors measurable or evaluable as outlined by modified RECIST or evaluable by CT or MRI scan. * Have an ECOG performance status of ≤ 2. * Have a life expectancy of at least 3 months. * Be ≥ 18 years old. * Have a negative pregnancy test (if female of childbearing potential) * Demonstrate acceptable hepatic function: * Bilirubin ≤ upper limit of normal (ULN) * AST (SGOT) and ALT (SGPT) ≤ 2.5 times ULN * Demonstrate acceptable renal function: * Serum creatinine ≤ 1.5 x ULN, OR calculated creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal (Calculated according to the Cockroft and Gault formula) * Demonstrate acceptable hematologic status: * Absolute neutrophil count ≥ 1500/mm3 * Platelet count ≥ 100,000/mm3 (measured within 72 hours prior to initial dose) * Hemoglobin ≥ 9 g/dL * Demonstrate acceptable coagulation status: * PT or INR within 1.5x ULN * PTT within 1.5x ULN * Have recovered from prior treatments (eg, surgery, radiation, chemotherapy, investigational therapies) sufficiently prior to Day 1 so that, in the opinion of the Investigator and/or Medical Monitor, the protocol objectives would not be compromised. * Agree to use an effective contraceptive method (hormonal or barrier method; or abstinence) for the duration of the study and for 30 days after the last dose (for men and women of child-producing potential). Exclusion Criteria: * Have New York Heart Association Class III or IV cardiac disease, myocardial infarction within the past 6 months prior to Day 1, unstable arrhythmia, or evidence of ischemia on electrocardiogram (ECG). * Have a seizure disorder requiring anticonvulsant therapy. * Have active CNS metastasis. Patients with a history of CNS metastases will be eligible if they have been treated and are stable without symptoms for 4 weeks after completion of treatment, with image documentation required, and must be either off steroids or on stable dose of steroids for ≥ 1 week prior to enrollment. * Have severe, chronic obstructive pulmonary disease with hypoxemia. * Have active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy. * Are pregnant or nursing. * Have undergone radiation therapy, surgery, chemotherapy, or investigational therapy within 28 days prior to study entry (6 weeks for nitrosoureas or Mitomycin C). * Are unwilling or unable to comply with procedures required in this protocol. * Have a known history of infection with HIV, hepatitis B, or hepatitis C. * Have a serious nonmalignant disease that, in the opinion of the Investigator and/or the Medical Monitor, could compromise protocol objectives. * Are currently receiving any other investigational agent. * Have exhibited allergic reactions to docetaxel, or a similar structural compound, biological agent, or formulation.